Recent Updates
Recently added Catalysts

BGB-B2033

Phase 3

Hepatocellular Carcinoma | Biologics | Oncology |BeOne Medicines Ltd.|Trials Updated: Nov 3, 2026

BGB-B2033 development status

Highest phase Phase 3
Registered trials 3 across 1 sponsor since May 2024

BGB-B2033 target and mechanism

Molecular targetGPC3
Target classProtein
ModalityBiologics

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedACTIVE_CONTROLLEDDMC
Total Trials3
Total Enrollment1,222

FDA Designations

FAST_TRACKORPHAN_DRUG

BGB-B2033 clinical trials

BGB-B2033 · 3 trials · 8 indications

Phase 3 1Phase 2 1Phase 1/2 1
NCT07836530Study Comparing BGB-B2033 With Sorafenib or Lenvatinib in Relapsed Hepatocellular CarcinomaHepatocellular Carcinoma
NOT YET_RECRUITING492 Analytics
PHASE3NOT YET_RECRUITING
Study Comparing BGB-B2033 With Sorafenib or Lenvatinib in Relapsed Hepatocellular Carcinoma
Hepatocellular CarcinomaUnlock trial analytics

Study Endpoints

Primary Endpoints

Overall Survival (OS)
Up to approximately 3.5 years

OS is defined as the time from randomization to the date of death from any cause.

Overall Response Assessment (ORR) by Independent Review Committee Assessment
Up to approximately 15 months

ORR is defined as the percentage of participants with best overall response of complete response (CR) or partial response (PR) with confirmation per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 based on Independent Review Committee (IRC) assessments.

Part A and B: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Up to approximately 2 years

Number of participants with AEs and SAEs characterized by type, frequency, severity (as graded by the National Cancer Institute- Common Terminology Criteria for Adverse Events Version 5.0 \[NCI-CTCAE v 5.0/American Society for Transplantation and Cellular Therapy \[ASTCT\] for cytokine release syndrome \[CRS\] and immune effector cell-associated neurotoxicity syndrome \[ICANS\]), timing, seriousness, and relationship to study therapy; assessment of adverse events meeting protocol-defined dose-limiting toxicity (DLT) criteria

Part A and B: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of BGB-B2033
Up to approximately 2 years

The MTD or MAD is defined as the highest dose that is tolerable or the highest dose administered, respectively.

Part A and B: Recommended Phase 2 dose (RP2D) of BGB-B2033
Up to approximately 2 years

The RP2D(s) will be determined based on a biologically effective dose by taking the totality of available preclinical and clinical data, including safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and antitumor activity, into consideration

Parts C, D, and E: Overall Response Rate (ORR) as assessed by the Independent Review Committee (IRC)
Up to approximately 2 years

ORR is defined as the percentage of participants with best overall response (BOR) of complete response (CR) or partial response (PR) using Response Evaluations Criteria in Solid Tumors Version 1.1 (RECIST v1.1).

Secondary Endpoints

Overall Response Rate (ORR)
Up to approximately 3.5 years
Duration of Response (DOR)
Up to approximately 3.5 years
Progression Free Survival Rate (PFS)
Up to approximately 3.5 years
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
BGB-B2033EXPERIMENTALParticipants are randomized to receive BGB-B2033 until disease progression, unacceptable toxicity, withdrawal of consent, death, or the end of the study, whichever occurs first.
Investigator's choice: Lenvatinib OR sorafenibACTIVE_COMPARATORParticipants are randomized to receive either lenvatinib or sorafenib, selected by the investigator before treatment, until disease progression, unacceptable toxicity, withdrawal of consent, death, or the end of the study, whichever occurs first.
BGB-B2033 MonotherapyEXPERIMENTALParticipants will receive BGB-B2033 intravenously until progressive disease, unacceptable toxicity, or withdrawal of consent.
Part A (Monotherapy Dose Escalation and Safety Expansion)EXPERIMENTALParticipants will receive ascending dose levels of BGB-B2033 monotherapy
Part B (Doublet Run-in)EXPERIMENTALParticipants will receive BGB-B2033 in combination with tislelizumab and to inform the starting dose of BGB-B2033 for subsequent triplet dose escalation.
Part B (Triplet Dose Escalation)EXPERIMENTALParticipants will receive BGB-B2033 in combination with tislelizumab and bevacizumab to determine the maximum tolerated dose (MTD), maximum administered dose (MAD), and recommended dose for expansion (RDFE) of the combination.
Part B (Triplet and Doublet Safety Expansion)EXPERIMENTALSafety expansion arm for each combination therapy cohort (triplet and doublet)
Part C (Asia Monotherapy Dose Expansion in HCC)EXPERIMENTALParticipants in Asian countries with HCC will receive BGB-B2033 as monotherapy.
Part D (US Monotherapy Dose Expansion in HCC)EXPERIMENTALParticipants in the United States (US) with HCC will receive BGB-B2033 as monotherapy.
Part E (Monotherapy Dose Expansion in HCC)EXPERIMENTALParticipants with HCC will receive BGB-B2033 as monotherapy.

Interventions

NameTypeDescription
BGB-B2033DRUGAdministered intravenously
LenvatinibDRUGAdministered by mouth as an oral capsule once daily
SorafenibDRUGAdministered by mouth as an oral tablet twice daily
TislelizumabDRUGAdministered by intravenous infusion
BevacizumabDRUGAdministered by intravenous infusion
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo

Key Inclusion Criteria: 1. Participants must have histologically confirmed Hepatocellular Carcinoma (HCC) that is not amenable to curative surgical or locoregional therapies. 2. Participants must have documented disease progression or intolerance after at least 1 but not exceeding 2 prior lines of ...

Countries:United StatesBrazilChinaFranceItalyJapanNew ZealandPuerto RicoSouth Korea
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWNov 3, 2026NCT07911683NEW_TRIAL: changed
LOWNov 3, 2026NCT07911683NEW_TRIAL: changed
LOWSep 23, 2026NCT07836530NEW_TRIAL: changed
LOWSep 23, 2026NCT07836530NEW_TRIAL: changed
LOWSep 23, 2026NCT07836530NEW_TRIAL: changed
LOWSep 16, 2026NCT06427941lastUpdatePostDate: changed
LOWSep 16, 2026NCT06427941lastUpdatePostDate: changed
MEDIUMSep 8, 2026NCT06427941Enrollment: 392 → 630
MEDIUMSep 8, 2026NCT06427941Enrollment: 392 → 630

Frequently asked questions about BGB-B2033

What is BGB-B2033 used for?

BGB-B2033 is being developed for hepatocellular carcinoma, including advanced and metastatic liver cancer. It is also being studied in other GPC3-positive tumors such as squamous non-small cell lung cancer, alpha-fetoprotein-producing gastric cancer, and extragonadal yolk sac tumors. It is an investigational biologic and has not been approved for any use.

What does BGB-B2033 target?

BGB-B2033 targets GPC3, or glypican-3, a cell surface protein. GPC3 is the molecular target of this biologic agent, and the clinical program includes a trial enrolling participants with GPC3-positive squamous non-small cell lung cancer alongside hepatocellular carcinoma cohorts.

Who is developing BGB-B2033?

BGB-B2033 is being developed by BeOne Medicines Ltd., which trades under the ticker ONC. The company is running the clinical program for the drug in hepatocellular carcinoma and other advanced solid tumors, including a Phase 1/2 study combining it with tislelizumab with or without bevacizumab.

What phase is BGB-B2033 in?

BGB-B2033 is in Phase 2 development for hepatocellular carcinoma, and a Phase 3 study has also been registered. The drug is investigational and is not FDA approved. It has received Fast Track and Orphan Drug designations from the FDA for its liver cancer program.

What clinical trials is BGB-B2033 in?

BGB-B2033 is studied in NCT06427941, a recruiting Phase 1/2 trial in advanced or metastatic solid tumors, alone or with tislelizumab with or without bevacizumab. NCT07911683 is a Phase 2 study in advanced hepatocellular carcinoma, and NCT07836530 is a Phase 3 study comparing BGB-B2033 with sorafenib or lenvatinib in relapsed hepatocellular carcinoma.

Is BGB-B2033 randomized and controlled?

The Phase 1/2 study of BGB-B2033, NCT06427941, is an uncontrolled, non-randomized, open-label design enrolling up to 630 participants across sites in the United States, Brazil, China, France, Italy, Japan, New Zealand, Puerto Rico, and South Korea. The registered Phase 3 study NCT07836530 plans 492 participants and compares BGB-B2033 with sorafenib or lenvatinib.